d3s-001 + cisplatin + pemetrexed

**d3s-001 + cisplatin + pemetrexed** is an investigational three-drug combination under clinical study for the treatment of advanced solid tumors, notably those harboring the **KRAS G12C genetic mutation**. The regimen consists of D3S-001, an oral next-generation, highly potent, covalent KRAS-G12C inhibitor developed to overcome resistance and provide rapid and complete engagement of the KRAS G12C target, combined with standard intravenous chemotherapy agents cisplatin (a platinum-based DNA crosslinker) and pemetrexed (an antifolate antineoplastic agent inhibiting thymidylate synthase and other folate-dependent enzymes)[1][2][3][4][5]. The combination is designed to leverage D3S-001’s targeted inhibition of oncogenic KRAS G12C alongside established chemotherapy’s cytotoxic effects, aiming for greater antitumor activity, higher disease control rates, and potential efficacy in resistant or previously treated cancers such as non-small cell lung cancer (NSCLC), colorectal cancer, and other advanced solid tumors[1][2][3][4][5].